Faron Pharmaceuticals Oy (GB:FARN)
LSE:FARN
UK Market
Advertisement

Faron Pharmaceuticals Oy (FARN) Drug Pipeline

Compare
39 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Azacitidine, Venetoclax, Bexmarilimab
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Relapsed/Refractory Aml, Chronic Myelomonocytic Leukemia
Phase I/II
Active Not Recruiting
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
Jun 15, 2022
Fp-1305 (Bexmarilimab)
Cancer
Phase I/II
Completed
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
Oct 23, 2018

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Faron Pharmaceuticals Oy (FARN) have in its pipeline
      FARN is currently developing the following drugs: Azacitidine, Venetoclax, Bexmarilimab, Fp-1305 (Bexmarilimab). These drug candidates are in various stages of clinical development as the company works toward FDA approval.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis